ID   SMN_HUMAN               Reviewed;         294 AA.
AC   Q16637; A8K0V4; Q13119; Q549U5; Q96J51;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   07-APR-2021, entry version 229.
DE   RecName: Full=Survival motor neuron protein;
DE   AltName: Full=Component of gems 1;
DE   AltName: Full=Gemin-1;
GN   Name=SMN1; Synonyms=SMN, SMNT;
GN   and
GN   Name=SMN2; Synonyms=SMNC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], ALTERNATIVE SPLICING, AND VARIANT
RP   SMA1 CYS-272.
RC   TISSUE=Fetal brain;
RX   PubMed=7813012; DOI=10.1016/0092-8674(95)90460-3;
RA   Lefebvre S., Buerglen L., Reboullet S., Clermont O., Burlet P., Viollet L.,
RA   Benichou B., Cruaud C., Millasseau P., Zeviani M., le Paslier D.,
RA   Frezal J., Cohen D., Weissenbach J., Munnich A., Melki J.;
RT   "Identification and characterization of a spinal muscular atrophy-
RT   determining gene.";
RL   Cell 80:155-165(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8838816; DOI=10.1006/geno.1996.0147;
RA   Buerglen L., Lefebvre S., Clermont O., Burlet P., Viollet L., Cruaud C.,
RA   Munnich A., Melki J.;
RT   "Structure and organization of the human survival motor neurone (SMN)
RT   gene.";
RL   Genomics 32:479-482(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9503025; DOI=10.1006/geno.1997.5141;
RA   Chen Q., Baird S.D., Mahadevan M., Besner-Johnston A., Farahani R.,
RA   Xuan J.-Y., Kang X., Lefebvre C., Ikeda J.-E., Korneluk R.G.,
RA   MacKenzie A.E.;
RT   "Sequence of a 131-kb region of 5q13.1 containing the spinal muscular
RT   atrophy candidate genes SMN and NAIP.";
RL   Genomics 48:121-127(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Skeletal muscle;
RX   PubMed=7639755; DOI=10.1006/bbrc.1995.2135;
RA   Gennarelli M., Lucarelli M., Capon F., Pizzuti A., Merlini L., Angelini C.,
RA   Novelli G., Dallapiccola B.;
RT   "Survival motor neuron gene transcript analysis in muscles from spinal
RT   muscular atrophy patients.";
RL   Biochem. Biophys. Res. Commun. 213:342-348(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SMN-DELTA7).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SMN AND SMN-DELTA7).
RC   TISSUE=Kidney, Lung, Placenta, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-294.
RX   PubMed=7552146; DOI=10.1159/000472281;
RA   van der Steege G., Draaijers T.G., Grootscholten P.M., Osinga J.,
RA   Anzevino R., Velona I., Den Dunnen J.T., Scheffer H., Brahe C.,
RA   van Ommen G.J.B., Buys C.H.C.M.;
RT   "A provisional transcript map of the spinal muscular atrophy (SMA) critical
RT   region.";
RL   Eur. J. Hum. Genet. 3:87-95(1995).
RN   [9]
RP   INVOLVEMENT IN SMA4.
RX   PubMed=7658877; DOI=10.1016/s0140-6736(95)91507-9;
RA   Brahe C., Servidei S., Zappata S., Ricci E., Tonali P., Neri G.;
RT   "Genetic homogeneity between childhood-onset and adult-onset autosomal
RT   recessive spinal muscular atrophy.";
RL   Lancet 346:741-742(1995).
RN   [10]
RP   INVOLVEMENT IN SMA4.
RX   PubMed=8551862; DOI=10.1016/s0140-6736(95)92881-2;
RA   Clermont O., Burlet P., Lefebvre S., Buerglen L., Munnich A., Melki J.;
RT   "SMN gene deletions in adult-onset spinal muscular atrophy.";
RL   Lancet 346:1712-1713(1995).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8670859; DOI=10.1002/j.1460-2075.1996.tb00725.x;
RA   Liu Q., Dreyfuss G.;
RT   "A novel nuclear structure containing the survival of motor neurons
RT   protein.";
RL   EMBO J. 15:3555-3565(1996).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=9259265; DOI=10.1093/hmg/6.8.1205;
RA   Coovert D.D., Le T.T., McAndrew P.E., Strasswimmer J., Crawford T.O.,
RA   Mendell J.R., Coulson S.E., Androphy E.J., Prior T.W., Burghes A.H.M.;
RT   "The survival motor neuron protein in spinal muscular atrophy.";
RL   Hum. Mol. Genet. 6:1205-1214(1997).
RN   [13]
RP   INTERACTION WITH GEMIN2.
RX   PubMed=9323129; DOI=10.1016/s0092-8674(00)80367-0;
RA   Liu Q., Fischer U., Wang F., Dreyfuss G.;
RT   "The spinal muscular atrophy disease gene product, SMN, and its associated
RT   protein SIP1 are in a complex with spliceosomal snRNP proteins.";
RL   Cell 90:1013-1021(1997).
RN   [14]
RP   FUNCTION IN U12 INTRONS SPLICING.
RX   PubMed=9845364; DOI=10.1016/s0092-8674(00)81632-3;
RA   Pellizzoni L., Kataoka N., Charroux B., Dreyfuss G.;
RT   "A novel function for SMN, the spinal muscular atrophy disease gene
RT   product, in pre-mRNA splicing.";
RL   Cell 95:615-624(1998).
RN   [15]
RP   INTERACTION WITH SYNCRIP.
RX   PubMed=11574476; DOI=10.1093/emboj/20.19.5443;
RA   Mourelatos Z., Abel L., Yong J., Kataoka N., Dreyfuss G.;
RT   "SMN interacts with a novel family of hnRNP and spliceosomal proteins.";
RL   EMBO J. 20:5443-5452(2001).
RN   [16]
RP   INTERACTION WITH COIL.
RX   PubMed=11641277; DOI=10.1101/gad.908401;
RA   Hebert M.D., Szymczyk P.W., Shpargel K.B., Matera A.G.;
RT   "Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular
RT   atrophy protein.";
RL   Genes Dev. 15:2720-2729(2001).
RN   [17]
RP   INTERACTION WITH OSTF1, AND TISSUE SPECIFICITY.
RX   PubMed=11551898; DOI=10.1074/jbc.m100233200;
RA   Kurihara N., Menaa C., Maeda H., Haile D.J., Reddy S.V.;
RT   "Osteoclast-stimulating factor interacts with the spinal muscular atrophy
RT   gene product to stimulate osteoclast formation.";
RL   J. Biol. Chem. 276:41035-41039(2001).
RN   [18]
RP   INTERACTION WITH ZPR1, AND SUBCELLULAR LOCATION.
RX   PubMed=11283611; DOI=10.1038/35070059;
RA   Gangwani L., Mikrut M., Theroux S., Sharma M., Davis R.J.;
RT   "Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN
RT   protein.";
RL   Nat. Cell Biol. 3:376-383(2001).
RN   [19]
RP   REVIEW, AND SUBCELLULAR LOCATION.
RX   PubMed=12067652; DOI=10.1016/s0955-0674(02)00332-0;
RA   Paushkin S., Gubitz A.K., Massenet S., Dreyfuss G.;
RT   "The SMN complex, an assemblyosome of ribonucleoproteins.";
RL   Curr. Opin. Cell Biol. 14:305-312(2002).
RN   [20]
RP   IDENTIFICATION IN AN IMPORT SNRNP COMPLEX, AND INTERACTION WITH DDX20;
RP   RNUT1 AND SNRPB.
RX   PubMed=12095920; DOI=10.1093/hmg/11.15.1785;
RA   Narayanan U., Ospina J.K., Frey M.R., Hebert M.D., Matera A.G.;
RT   "SMN, the spinal muscular atrophy protein, forms a pre-import snRNP complex
RT   with snurportin1 and importin beta.";
RL   Hum. Mol. Genet. 11:1785-1795(2002).
RN   [21]
RP   INTERACTION WITH GEMIN FAMILY MEMBERS.
RX   PubMed=12065586; DOI=10.1074/jbc.m203478200;
RA   Baccon J., Pellizzoni L., Rappsilber J., Mann M., Dreyfuss G.;
RT   "Identification and characterization of Gemin7, a novel component of the
RT   survival of motor neuron complex.";
RL   J. Biol. Chem. 277:31957-31962(2002).
RN   [22]
RP   INTERACTION WITH LSM11.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=12975319; DOI=10.1101/gad.274403;
RA   Pillai R.S., Grimmler M., Meister G., Will C.L., Luehrmann R., Fischer U.,
RA   Schuemperli D.;
RT   "Unique Sm core structure of U7 snRNPs: assembly by a specialized SMN
RT   complex and the role of a new component, Lsm11, in histone RNA
RT   processing.";
RL   Genes Dev. 17:2321-2333(2003).
RN   [23]
RP   SUBUNIT, INTERACTION WITH RPP20/POP7, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   GLU-134, CHARACTERIZATION OF VARIANTS SMA1 CYS-272 AND VAL-279,
RP   CHARACTERIZATION OF VARIANT SMA2 AND SMA3 ILE-274, AND CHARACTERIZATION OF
RP   VARIANT SMA3 ILE-262.
RX   PubMed=14715275; DOI=10.1016/j.bbrc.2003.12.084;
RA   Hua Y., Zhou J.;
RT   "Rpp20 interacts with SMN and is re-distributed into SMN granules in
RT   response to stress.";
RL   Biochem. Biophys. Res. Commun. 314:268-276(2004).
RN   [24]
RP   INTERACTION WITH LSM10; LSM11 AND SNRPB.
RX   PubMed=16087681; DOI=10.1074/jbc.m505077200;
RA   Azzouz T.N., Pillai R.S., Dapp C., Chari A., Meister G., Kambach C.,
RA   Fischer U., Schuemperli D.;
RT   "Toward an assembly line for U7 snRNPs: interactions of U7-specific Lsm
RT   proteins with PRMT5 and SMN complexes.";
RL   J. Biol. Chem. 280:34435-34440(2005).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate cancer
RT   cells: identification of phosphoproteins in the LNCaP cell line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [27]
RP   FUNCTION IN SNRNP BIOGENESIS, AND IDENTIFICATION IN SMN-SM COMPLEX.
RX   PubMed=18984161; DOI=10.1016/j.cell.2008.09.020;
RA   Chari A., Golas M.M., Klingenhager M., Neuenkirchen N., Sander B.,
RA   Englbrecht C., Sickmann A., Stark H., Fischer U.;
RT   "An assembly chaperone collaborates with the SMN complex to generate
RT   spliceosomal SnRNPs.";
RL   Cell 135:497-509(2008).
RN   [28]
RP   INTERACTION WITH FMR1, AND SUBCELLULAR LOCATION.
RX   PubMed=18093976; DOI=10.1074/jbc.m707304200;
RA   Piazzon N., Rage F., Schlotter F., Moine H., Branlant C., Massenet S.;
RT   "In vitro and in cellulo evidences for association of the survival of motor
RT   neuron complex with the fragile X mental retardation protein.";
RL   J. Biol. Chem. 283:5598-5610(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-8; THR-25; SER-28 AND SER-31,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-25; SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-25; SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-25; SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [35]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH WRAP53.
RX   PubMed=21072240; DOI=10.1371/journal.pbio.1000521;
RA   Mahmoudi S., Henriksson S., Weibrecht I., Smith S., Soederberg O.,
RA   Stroemblad S., Wiman K.G., Farnebo M.;
RT   "WRAP53 is essential for Cajal body formation and for targeting the
RT   survival of motor neuron complex to Cajal bodies.";
RL   PLoS Biol. 8:E1000521-E1000521(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   PHOSPHORYLATION AT SER-4; SER-5; SER-8; THR-85 AND SER-187 BY PKA.
RX   PubMed=21609790; DOI=10.1016/j.bbapap.2011.04.015;
RA   Wu C.Y., Curtis A., Choi Y.S., Maeda M., Xu M.J., Berg A., Joneja U.,
RA   Mason R.W., Lee K.H., Wang W.;
RT   "Identification of the phosphorylation sites in the survival motor neuron
RT   protein by protein kinase A.";
RL   Biochim. Biophys. Acta 1814:1134-1139(2011).
RN   [38]
RP   INTERACTION WITH SETX.
RX   PubMed=21700224; DOI=10.1016/j.molcel.2011.04.026;
RA   Skourti-Stathaki K., Proudfoot N.J., Gromak N.;
RT   "Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause
RT   sites to promote Xrn2-dependent termination.";
RL   Mol. Cell 42:794-805(2011).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-4; SER-5; SER-8 AND SER-28, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [40]
RP   FUNCTION.
RX   PubMed=23063131; DOI=10.1016/j.cell.2012.09.012;
RA   Lotti F., Imlach W.L., Saieva L., Beck E.S., Hao le T., Li D.K., Jiao W.,
RA   Mentis G.Z., Beattie C.E., McCabe B.D., Pellizzoni L.;
RT   "An SMN-dependent U12 splicing event essential for motor circuit
RT   function.";
RL   Cell 151:440-454(2012).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4; SER-8; THR-25; SER-28;
RP   SER-31 AND THR-69, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-25; SER-28 AND SER-31, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [45]
RP   INTERACTION WITH SF3B2.
RX   PubMed=25737013; DOI=10.1038/ncomms7428;
RA   Yang Y., Hadjikyriacou A., Xia Z., Gayatri S., Kim D., Zurita-Lopez C.,
RA   Kelly R., Guo A., Li W., Clarke S.G., Bedford M.T.;
RT   "PRMT9 is a type II methyltransferase that methylates the splicing factor
RT   SAP145.";
RL   Nat. Commun. 6:6428-6428(2015).
RN   [46]
RP   FUNCTION, AND INTERACTION WITH POLR2A; PRMT5; SETX AND XRN2.
RX   PubMed=26700805; DOI=10.1038/nature16469;
RA   Yanling Zhao D., Gish G., Braunschweig U., Li Y., Ni Z., Schmitges F.W.,
RA   Zhong G., Liu K., Li W., Moffat J., Vedadi M., Min J., Pawson T.J.,
RA   Blencowe B.J., Greenblatt J.F.;
RT   "SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal
RT   domain control termination.";
RL   Nature 529:48-53(2016).
RN   [47]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-51 AND LYS-209, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [48]
RP   STRUCTURE BY NMR OF 82-169.
RX   PubMed=11135666; DOI=10.1038/83014;
RA   Selenko P., Sprangers R., Stier G., Buhler D., Fischer U., Sattler M.;
RT   "SMN tudor domain structure and its interaction with the Sm proteins.";
RL   Nat. Struct. Biol. 8:27-31(2001).
RN   [49]
RP   STRUCTURE BY NMR OF 84-147 IN COMPLEX WITH DIMETHYLATED ARGININE.
RX   PubMed=22101937; DOI=10.1038/nsmb.2185;
RA   Tripsianes K., Madl T., Machyna M., Fessas D., Englbrecht C., Fischer U.,
RA   Neugebauer K.M., Sattler M.;
RT   "Structural basis for dimethylarginine recognition by the Tudor domains of
RT   human SMN and SPF30 proteins.";
RL   Nat. Struct. Mol. Biol. 18:1414-1420(2011).
RN   [50]
RP   VARIANT SMA1 VAL-279.
RX   PubMed=9147655; DOI=10.1093/hmg/6.3.497;
RA   Talbot K., Ponting C.P., Theodosiou A.M., Rodriques N.R., Surtees R.,
RA   Mountford R., Davies K.E.;
RT   "Missense mutation clustering in the survival motor neuron gene: a role for
RT   a conserved tyrosine and glycine rich region of the protein in RNA
RT   metabolism?";
RL   Hum. Mol. Genet. 6:497-500(1997).
RN   [51]
RP   VARIANT SMA3 ILE-262, AND VARIANT SMA2/SMA3 ILE-274.
RX   PubMed=9158159; DOI=10.1093/hmg/6.5.821;
RA   Hahnen E., Schoenling J., Rudnik-Schoeneborn S., Raschke H., Zerres K.,
RA   Wirth B.;
RT   "Missense mutations in exon 6 of the survival motor neuron gene in patients
RT   with spinal muscular atrophy (SMA).";
RL   Hum. Mol. Genet. 6:821-825(1997).
RN   [52]
RP   VARIANT SMA3 LEU-245, AND VARIANT SMA1 CYS-272.
RX   PubMed=10732817; DOI=10.1007/s100480050021;
RA   Rochette C.F., Surh L.C., Ray P.N., McAndrew P.E., Prior T.W.,
RA   Burghes A.H.M., Vanasse M., Simard L.R.;
RT   "Molecular diagnosis of non-deletion SMA patients using quantitative PCR of
RT   SMN exon 7.";
RL   Neurogenetics 1:141-147(1997).
RN   [53]
RP   VARIANT SMA2/SMA3 GLY-2, AND VARIANT SMA3 SER-275.
RX   PubMed=9837824; DOI=10.1086/302160;
RA   Parsons D.W., McAndrew P.E., Iannaccone S.T., Mendell J.R., Burghes A.H.,
RA   Prior T.W.;
RT   "Intragenic telSMN mutations: frequency, distribution, evidence of a
RT   founder effect, and modification of the spinal muscular atrophy phenotype
RT   by cenSMN copy number.";
RL   Am. J. Hum. Genet. 63:1712-1723(1998).
RN   [54]
RP   VARIANT SMA2/SMA3 CYS-279.
RX   PubMed=10732802; DOI=10.1007/s100480050040;
RA   Wang C.H., Papendick B.D., Bruinsma P., Day J.K.;
RT   "Identification of a novel missense mutation of the smnt gene in two
RT   siblings with spinal muscular atrophy.";
RL   Neurogenetics 1:273-276(1998).
RN   [55]
RP   VARIANTS SMA1 PHE-116 AND GLU-136.
RX   PubMed=15249625; DOI=10.1212/01.wnl.0000132634.48815.13;
RA   Cusco I., Barcelo M.J., del Rio E., Baiget M., Tizzano E.F.;
RT   "Detection of novel mutations in the SMN Tudor domain in type I SMA
RT   patients.";
RL   Neurology 63:146-149(2004).
RN   [56]
RP   VARIANTS SMA1/SMA2/SMA3 ASN-30; VAL-44; ARG-95; GLY-111; GLY-262; CYS-272
RP   AND ILE-274, AND CHARACTERIZATION OF VARIANTS SMA1/SMA2/SMA3 ASN-30;
RP   VAL-44; ARG-95 AND GLY-111.
RX   PubMed=15580564; DOI=10.1002/humu.20111;
RA   Sun Y., Grimmler M., Schwarzer V., Schoenen F., Fischer U., Wirth B.;
RT   "Molecular and functional analysis of intragenic SMN1 mutations in patients
RT   with spinal muscular atrophy.";
RL   Hum. Mutat. 25:64-71(2005).
RN   [57]
RP   INTERACTION WITH ELAVL4, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANTS
RP   SMA2 GLU-111; SMA1 PHE-116 AND SMA1 GLU-136, AND MUTAGENESIS OF GLU-134.
RX   PubMed=21088113; DOI=10.1093/hmg/ddq500;
RA   Hubers L., Valderrama-Carvajal H., Laframboise J., Timbers J., Sanchez G.,
RA   Cote J.;
RT   "HuD interacts with survival motor neuron protein and can rescue spinal
RT   muscular atrophy-like neuronal defects.";
RL   Hum. Mol. Genet. 20:553-579(2011).
RN   [58]
RP   INTERACTION WITH ELAVL4, VARIANT SMA1 VAL-279, AND MUTAGENESIS OF GLU-134.
RX   PubMed=21389246; DOI=10.1523/jneurosci.3631-10.2011;
RA   Fallini C., Zhang H., Su Y., Silani V., Singer R.H., Rossoll W.,
RA   Bassell G.J.;
RT   "The survival of motor neuron (SMN) protein interacts with the mRNA-binding
RT   protein HuD and regulates localization of poly(A) mRNA in primary motor
RT   neuron axons.";
RL   J. Neurosci. 31:3914-3925(2011).
RN   [59]
RP   INTERACTION WITH ELAVL4, AND MUTAGENESIS OF GLU-134.
RX   PubMed=29061699; DOI=10.1523/jneurosci.1528-17.2017;
RA   Hao le T., Duy P.Q., An M., Talbot J., Iyer C.C., Wolman M., Beattie C.E.;
RT   "HuD and the Survival Motor Neuron Protein Interact in Motoneurons and Are
RT   Essential for Motoneuron Development, Function, and mRNA Regulation.";
RL   J. Neurosci. 37:11559-11571(2017).
CC   -!- FUNCTION: The SMN complex plays a catalyst role in the assembly of
CC       small nuclear ribonucleoproteins (snRNPs), the building blocks of the
CC       spliceosome. Thereby, plays an important role in the splicing of
CC       cellular pre-mRNAs. Most spliceosomal snRNPs contain a common set of Sm
CC       proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that
CC       assemble in a heptameric protein ring on the Sm site of the small
CC       nuclear RNA to form the core snRNP. In the cytosol, the Sm proteins
CC       SNRPD1, SNRPD2, SNRPE, SNRPF and SNRPG are trapped in an inactive 6S
CC       pICln-Sm complex by the chaperone CLNS1A that controls the assembly of
CC       the core snRNP. Dissociation by the SMN complex of CLNS1A from the
CC       trapped Sm proteins and their transfer to an SMN-Sm complex triggers
CC       the assembly of core snRNPs and their transport to the nucleus. Ensures
CC       the correct splicing of U12 intron-containing genes that may be
CC       important for normal motor and proprioceptive neurons development. Also
CC       required for resolving RNA-DNA hybrids created by RNA polymerase II,
CC       that form R-loop in transcription terminal regions, an important step
CC       in proper transcription termination. May also play a role in the
CC       metabolism of small nucleolar ribonucleoprotein (snoRNPs).
CC       {ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:23063131,
CC       ECO:0000269|PubMed:26700805, ECO:0000269|PubMed:9845364}.
CC   -!- SUBUNIT: Homodimer (PubMed:14715275). Part of the core SMN complex that
CC       contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5, GEMIN6,
CC       GEMIN7, GEMIN8 and STRAP/UNRIP (PubMed:9323129). Part of the SMN-Sm
CC       complex that contains SMN1, GEMIN2/SIP1, DDX20/GEMIN3, GEMIN4, GEMIN5,
CC       GEMIN6, GEMIN7, GEMIN8, STRAP/UNRIP and the Sm proteins SNRPB, SNRPD1,
CC       SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG (PubMed:12065586,
CC       PubMed:18984161). Component of an import snRNP complex composed of
CC       KPNB1, RNUT1, SMN1 and ZNF259 (PubMed:12095920). Interacts with DDX20,
CC       FBL, NOLA1, RNUT1, SYNCRIP and with several spliceosomal snRNP core Sm
CC       proteins, including SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE and ILF3
CC       (PubMed:11574476, PubMed:12095920). Interacts with OSTF1, LSM10, LSM11
CC       and RPP20/POP7 (PubMed:11551898, PubMed:12975319, PubMed:16087681,
CC       PubMed:14715275). Interacts (via C-terminal region) with ZPR1 (via C-
CC       terminal region) (PubMed:11283611). Interacts (via Tudor domain) with
CC       COIL (PubMed:11641277). Interacts with SETX; recruits SETX to POLR2A
CC       (PubMed:21700224, PubMed:26700805). Interacts with POLR2A (via the C-
CC       terminal domain (CTD)) (PubMed:26700805). Interacts with PRMT5
CC       (PubMed:26700805). Interacts with XRN2 (PubMed:26700805). Interacts
CC       (via C-terminus) with FMR1 (via C-terminus); the interaction is direct
CC       and occurs in a RNA-independent manner (PubMed:18093976). Interacts
CC       (via Tudor domain) with SF3B2 ('Arg-508'-methylated form)
CC       (PubMed:25737013). Interacts with WRAP53/TCAB1 (PubMed:21072240).
CC       Interacts (via Tudor domain) with ELAVL4 in an RNA-independent manner;
CC       the interaction is required for localization of ELAVL4 to RNA granules
CC       (PubMed:21088113, PubMed:21389246, PubMed:29061699).
CC       {ECO:0000269|PubMed:11283611, ECO:0000269|PubMed:11551898,
CC       ECO:0000269|PubMed:11574476, ECO:0000269|PubMed:11641277,
CC       ECO:0000269|PubMed:12065586, ECO:0000269|PubMed:12095920,
CC       ECO:0000269|PubMed:12975319, ECO:0000269|PubMed:14715275,
CC       ECO:0000269|PubMed:16087681, ECO:0000269|PubMed:18093976,
CC       ECO:0000269|PubMed:18984161, ECO:0000269|PubMed:21072240,
CC       ECO:0000269|PubMed:21088113, ECO:0000269|PubMed:21389246,
CC       ECO:0000269|PubMed:21700224, ECO:0000269|PubMed:25737013,
CC       ECO:0000269|PubMed:26700805, ECO:0000269|PubMed:29061699,
CC       ECO:0000269|PubMed:9323129}.
CC   -!- INTERACTION:
CC       Q16637; Q6PCB6: ABHD17C; NbExp=3; IntAct=EBI-395421, EBI-22011868;
CC       Q16637; Q96GX9: APIP; NbExp=3; IntAct=EBI-395421, EBI-359248;
CC       Q16637; Q96DX5: ASB9; NbExp=3; IntAct=EBI-395421, EBI-745641;
CC       Q16637; Q8WXF7: ATL1; NbExp=3; IntAct=EBI-395421, EBI-2410266;
CC       Q16637; Q9UL45: BLOC1S6; NbExp=6; IntAct=EBI-395421, EBI-465781;
CC       Q16637; Q13895: BYSL; NbExp=8; IntAct=EBI-395421, EBI-358049;
CC       Q16637; Q96FZ7: CHMP6; NbExp=3; IntAct=EBI-395421, EBI-1049648;
CC       Q16637; Q9Y3Y2: CHTOP; NbExp=3; IntAct=EBI-395421, EBI-347794;
CC       Q16637; Q9Y3Y2-3: CHTOP; NbExp=3; IntAct=EBI-395421, EBI-11984237;
CC       Q16637; P38432: COIL; NbExp=4; IntAct=EBI-395421, EBI-945751;
CC       Q16637; Q9NR90-2: DAZ3; NbExp=3; IntAct=EBI-395421, EBI-25830216;
CC       Q16637; Q9UHI6: DDX20; NbExp=10; IntAct=EBI-395421, EBI-347658;
CC       Q16637; Q08426: EHHADH; NbExp=3; IntAct=EBI-395421, EBI-2339219;
CC       Q16637; O75616: ERAL1; NbExp=3; IntAct=EBI-395421, EBI-6393536;
CC       Q16637; Q8IZU0: FAM9B; NbExp=8; IntAct=EBI-395421, EBI-10175124;
CC       Q16637; Q9UHY8: FEZ2; NbExp=3; IntAct=EBI-395421, EBI-396453;
CC       Q16637; Q9BVV2: FNDC11; NbExp=3; IntAct=EBI-395421, EBI-744935;
CC       Q16637; Q6PIV2: FOXR1; NbExp=3; IntAct=EBI-395421, EBI-10253815;
CC       Q16637; P06241-3: FYN; NbExp=3; IntAct=EBI-395421, EBI-10691738;
CC       Q16637; O14893: GEMIN2; NbExp=20; IntAct=EBI-395421, EBI-443648;
CC       Q16637; Q8TEQ6: GEMIN5; NbExp=7; IntAct=EBI-395421, EBI-443630;
CC       Q16637; Q8WVV9-3: HNRNPLL; NbExp=3; IntAct=EBI-395421, EBI-25845242;
CC       Q16637; Q9BUJ2: HNRNPUL1; NbExp=4; IntAct=EBI-395421, EBI-1018153;
CC       Q16637; P09017: HOXC4; NbExp=3; IntAct=EBI-395421, EBI-3923226;
CC       Q16637; Q6DN90-2: IQSEC1; NbExp=3; IntAct=EBI-395421, EBI-21911304;
CC       Q16637; Q8NA54: IQUB; NbExp=6; IntAct=EBI-395421, EBI-10220600;
CC       Q16637; Q14974-1: KPNB1; NbExp=2; IntAct=EBI-395421, EBI-15488647;
CC       Q16637; Q3SY46: KRTAP13-3; NbExp=3; IntAct=EBI-395421, EBI-10241252;
CC       Q16637; Q8IUB9: KRTAP19-1; NbExp=3; IntAct=EBI-395421, EBI-12811111;
CC       Q16637; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-395421, EBI-1048945;
CC       Q16637; Q3LI70: KRTAP19-6; NbExp=3; IntAct=EBI-395421, EBI-12805508;
CC       Q16637; Q3SYF9: KRTAP19-7; NbExp=6; IntAct=EBI-395421, EBI-10241353;
CC       Q16637; Q3LI59: KRTAP21-2; NbExp=3; IntAct=EBI-395421, EBI-18395721;
CC       Q16637; Q3LI64: KRTAP6-1; NbExp=3; IntAct=EBI-395421, EBI-12111050;
CC       Q16637; Q3LI66: KRTAP6-2; NbExp=5; IntAct=EBI-395421, EBI-11962084;
CC       Q16637; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-395421, EBI-10261141;
CC       Q16637; Q9Y5V3: MAGED1; NbExp=3; IntAct=EBI-395421, EBI-716006;
CC       Q16637; Q99683: MAP3K5; NbExp=3; IntAct=EBI-395421, EBI-476263;
CC       Q16637; Q15759: MAPK11; NbExp=3; IntAct=EBI-395421, EBI-298304;
CC       Q16637; Q9UBB5: MBD2; NbExp=2; IntAct=EBI-395421, EBI-923391;
CC       Q16637; Q8TDB4: MGARP; NbExp=3; IntAct=EBI-395421, EBI-4397720;
CC       Q16637; O43196-2: MSH5; NbExp=3; IntAct=EBI-395421, EBI-25844576;
CC       Q16637; Q9NV92: NDFIP2; NbExp=3; IntAct=EBI-395421, EBI-2933200;
CC       Q16637; Q9NPJ8-3: NXT2; NbExp=3; IntAct=EBI-395421, EBI-10698339;
CC       Q16637; O75925: PIAS1; NbExp=3; IntAct=EBI-395421, EBI-629434;
CC       Q16637; O15160: POLR1C; NbExp=6; IntAct=EBI-395421, EBI-1055079;
CC       Q16637; P24928: POLR2A; NbExp=12; IntAct=EBI-395421, EBI-295301;
CC       Q16637; O75817: POP7; NbExp=5; IntAct=EBI-395421, EBI-366574;
CC       Q16637; Q13427: PPIG; NbExp=4; IntAct=EBI-395421, EBI-396072;
CC       Q16637; Q86UA1: PRPF39; NbExp=3; IntAct=EBI-395421, EBI-2803203;
CC       Q16637; P57729: RAB38; NbExp=3; IntAct=EBI-395421, EBI-6552718;
CC       Q16637; Q7Z333: SETX; NbExp=3; IntAct=EBI-395421, EBI-1220123;
CC       Q16637; Q13435: SF3B2; NbExp=4; IntAct=EBI-395421, EBI-749111;
CC       Q16637; Q2NKQ1-4: SGSM1; NbExp=3; IntAct=EBI-395421, EBI-10182463;
CC       Q16637; Q12824: SMARCB1; NbExp=3; IntAct=EBI-395421, EBI-358419;
CC       Q16637; Q16637: SMN2; NbExp=21; IntAct=EBI-395421, EBI-395421;
CC       Q16637; Q16637-3: SMN2; NbExp=3; IntAct=EBI-395421, EBI-395447;
CC       Q16637; P08621: SNRNP70; NbExp=5; IntAct=EBI-395421, EBI-1049228;
CC       Q16637; P62314: SNRPD1; NbExp=6; IntAct=EBI-395421, EBI-372177;
CC       Q16637; P55769: SNU13; NbExp=3; IntAct=EBI-395421, EBI-712228;
CC       Q16637; O60749: SNX2; NbExp=3; IntAct=EBI-395421, EBI-1046690;
CC       Q16637; Q5MJ10: SPANXN2; NbExp=3; IntAct=EBI-395421, EBI-12023934;
CC       Q16637; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-395421, EBI-10696971;
CC       Q16637; P37802: TAGLN2; NbExp=3; IntAct=EBI-395421, EBI-1056740;
CC       Q16637; Q9NX07-2: TRNAU1AP; NbExp=3; IntAct=EBI-395421, EBI-21894090;
CC       Q16637; Q99598: TSNAX; NbExp=3; IntAct=EBI-395421, EBI-742638;
CC       Q16637; Q548N1: VPS28; NbExp=3; IntAct=EBI-395421, EBI-10243107;
CC       Q16637; Q9UK41: VPS28; NbExp=5; IntAct=EBI-395421, EBI-727424;
CC       Q16637; Q9BUR4: WRAP53; NbExp=5; IntAct=EBI-395421, EBI-2563542;
CC       Q16637; Q9VV74: Smn; Xeno; NbExp=2; IntAct=EBI-395421, EBI-185315;
CC       Q16637; A0A142I5B9; Xeno; NbExp=2; IntAct=EBI-395421, EBI-20625235;
CC       Q16637-2; O14893: GEMIN2; NbExp=4; IntAct=EBI-16014970, EBI-443648;
CC       Q16637-3; P01023: A2M; NbExp=3; IntAct=EBI-395447, EBI-640741;
CC       Q16637-3; P50570-2: DNM2; NbExp=3; IntAct=EBI-395447, EBI-10968534;
CC       Q16637-3; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-395447, EBI-11110431;
CC       Q16637-3; O43464: HTRA2; NbExp=3; IntAct=EBI-395447, EBI-517086;
CC       Q16637-3; P42858: HTT; NbExp=9; IntAct=EBI-395447, EBI-466029;
CC       Q16637-3; Q14974: KPNB1; NbExp=5; IntAct=EBI-395447, EBI-286758;
CC       Q16637-3; P51608: MECP2; NbExp=3; IntAct=EBI-395447, EBI-1189067;
CC       Q16637-3; P14678-1: SNRPB; NbExp=3; IntAct=EBI-395447, EBI-372471;
CC       Q16637-3; Q9UK41: VPS28; NbExp=3; IntAct=EBI-395447, EBI-727424;
CC   -!- SUBCELLULAR LOCATION: Nucleus, gem {ECO:0000269|PubMed:11283611,
CC       ECO:0000269|PubMed:8670859, ECO:0000305|PubMed:12067652}. Nucleus,
CC       Cajal body {ECO:0000269|PubMed:11283611, ECO:0000269|PubMed:21072240,
CC       ECO:0000305|PubMed:12067652}. Cytoplasm {ECO:0000269|PubMed:11283611,
CC       ECO:0000269|PubMed:8670859, ECO:0000305|PubMed:12067652}. Cytoplasmic
CC       granule {ECO:0000269|PubMed:14715275}. Perikaryon
CC       {ECO:0000269|PubMed:18093976}. Cell projection, neuron projection
CC       {ECO:0000269|PubMed:18093976}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P97801}. Cytoplasm, myofibril, sarcomere, Z line
CC       {ECO:0000250|UniProtKB:P97801}. Note=Colocalizes with actin and at the
CC       Z-line of skeletal muscle (By similarity). Under stress conditions
CC       colocalizes with RPP20/POP7 in punctuated cytoplasmic granules
CC       (PubMed:14715275). Colocalized and redistributed with ZPR1 from the
CC       cytoplasm to nuclear gems (Gemini of coiled bodies) and Cajal bodies
CC       (PubMed:11283611). Colocalizes with FMR1 in cytoplasmic granules in the
CC       soma and neurite cell processes (PubMed:18093976).
CC       {ECO:0000250|UniProtKB:P97801, ECO:0000269|PubMed:11283611,
CC       ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:18093976}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Experimental confirmation may be lacking for some isoforms.;
CC       Name=SMN; Synonyms=Full-SMN;
CC         IsoId=Q16637-1; Sequence=Displayed;
CC       Name=SMN-delta5; Synonyms=Iso5-SMN;
CC         IsoId=Q16637-2; Sequence=VSP_006183;
CC       Name=SMN-delta7; Synonyms=Iso7-SMN;
CC         IsoId=Q16637-3; Sequence=VSP_006184, VSP_006185;
CC       Name=SMN-delta57; Synonyms=Iso57-SMN;
CC         IsoId=Q16637-4; Sequence=VSP_006183, VSP_006184, VSP_006185;
CC   -!- TISSUE SPECIFICITY: Expressed in a wide variety of tissues. Expressed
CC       at high levels in brain, kidney and liver, moderate levels in skeletal
CC       and cardiac muscle, and low levels in fibroblasts and lymphocytes. Also
CC       seen at high levels in spinal cord. Present in osteoclasts and
CC       mononuclear cells (at protein level). {ECO:0000269|PubMed:11551898,
CC       ECO:0000269|PubMed:9259265}.
CC   -!- DOMAIN: The Tudor domain mediates association with dimethylarginines,
CC       which are common in snRNP proteins.
CC   -!- DISEASE: Spinal muscular atrophy 1 (SMA1) [MIM:253300]: A form of
CC       spinal muscular atrophy, a group of neuromuscular disorder
CC       characterized by degeneration of the anterior horn cells of the spinal
CC       cord, leading to symmetrical muscle weakness and atrophy. Autosomal
CC       recessive forms are classified according to the age of onset, the
CC       maximum muscular activity achieved, and survivorship. The severity of
CC       the disease is mainly determined by the copy number of SMN2, a copy
CC       gene which predominantly produces exon 7-skipped transcripts and only
CC       low amount of full-length transcripts that encode for a protein
CC       identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy
CC       with an intragenic mutation. SMA1 is a severe form, with onset before 6
CC       months of age. SMA1 patients never achieve the ability to sit.
CC       {ECO:0000269|PubMed:10732817, ECO:0000269|PubMed:14715275,
CC       ECO:0000269|PubMed:15249625, ECO:0000269|PubMed:15580564,
CC       ECO:0000269|PubMed:21088113, ECO:0000269|PubMed:21389246,
CC       ECO:0000269|PubMed:7813012, ECO:0000269|PubMed:9147655}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Spinal muscular atrophy 2 (SMA2) [MIM:253550]: An autosomal
CC       recessive form of spinal muscular atrophy, a neuromuscular disorder
CC       characterized by degeneration of the anterior horn cells of the spinal
CC       cord, leading to symmetrical muscle weakness and atrophy. It has
CC       intermediate severity, with onset between 6 and 18 months. Patients do
CC       not reach the motor milestone of standing, and survive into adulthood.
CC       {ECO:0000269|PubMed:10732802, ECO:0000269|PubMed:14715275,
CC       ECO:0000269|PubMed:21088113, ECO:0000269|PubMed:9158159,
CC       ECO:0000269|PubMed:9837824}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Spinal muscular atrophy 3 (SMA3) [MIM:253400]: An autosomal
CC       recessive form of spinal muscular atrophy, a neuromuscular disorder
CC       characterized by degeneration of the anterior horn cells of the spinal
CC       cord, leading to symmetrical muscle weakness and atrophy. Onset is
CC       after 18 months. Patients develop ability to stand and walk and survive
CC       into adulthood. {ECO:0000269|PubMed:10732817,
CC       ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:9158159,
CC       ECO:0000269|PubMed:9837824}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Spinal muscular atrophy 4 (SMA4) [MIM:271150]: An autosomal
CC       recessive form of spinal muscular atrophy, a neuromuscular disorder
CC       characterized by degeneration of the anterior horn cells of the spinal
CC       cord, leading to symmetrical muscle weakness and atrophy. Onset is in
CC       adulthood, disease progression is slow, and patients can stand and
CC       walk. {ECO:0000269|PubMed:7658877, ECO:0000269|PubMed:8551862}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: The SMN gene is present in two highly homologous and
CC       functional copies (TelSMN/SMN1 and CenSMN/SMN2). The telomeric copy of
CC       SMN gene (TelSMN/SMN1) seems to be the SMA-determining gene while the
CC       centromeric copy seems unaffected.
CC   -!- MISCELLANEOUS: [Isoform SMN]: Primarily derived from SMN1 gene.
CC   -!- MISCELLANEOUS: [Isoform SMN-delta7]: Thought to be a non-functional
CC       protein that lacks the capacity to oligomerize and thus cannot interact
CC       with Sm proteins. Primarily derived from SMN2 gene. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the SMN family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=SMN1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43883; AAC50473.1; -; Genomic_DNA.
DR   EMBL; U43876; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U43877; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U43878; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U43880; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U43881; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U43882; AAC50473.1; JOINED; Genomic_DNA.
DR   EMBL; U18423; AAA66242.1; -; mRNA.
DR   EMBL; U80017; AAC52048.1; -; Genomic_DNA.
DR   EMBL; AK289669; BAF82358.1; -; mRNA.
DR   EMBL; AC004999; AAC83178.1; -; Genomic_DNA.
DR   EMBL; AC005031; AAC62262.1; -; Genomic_DNA.
DR   EMBL; U21914; AAA64505.1; -; mRNA.
DR   EMBL; BC000908; AAH00908.1; -; mRNA.
DR   EMBL; BC015308; AAH15308.1; -; mRNA.
DR   EMBL; BC062723; AAH62723.1; -; mRNA.
DR   EMBL; BC070242; AAH70242.1; -; mRNA.
DR   CCDS; CCDS34181.1; -. [Q16637-1]
DR   CCDS; CCDS34182.1; -. [Q16637-2]
DR   CCDS; CCDS4007.1; -. [Q16637-1]
DR   CCDS; CCDS4008.1; -. [Q16637-2]
DR   CCDS; CCDS54867.1; -. [Q16637-3]
DR   CCDS; CCDS75256.1; -. [Q16637-3]
DR   PIR; A55477; A55477.
DR   RefSeq; NP_000335.1; NM_000344.3. [Q16637-1]
DR   RefSeq; NP_001284644.1; NM_001297715.1. [Q16637-3]
DR   RefSeq; NP_059107.1; NM_017411.3. [Q16637-1]
DR   RefSeq; NP_075012.1; NM_022874.2. [Q16637-2]
DR   RefSeq; NP_075013.1; NM_022875.2. [Q16637-3]
DR   RefSeq; NP_075014.1; NM_022876.2. [Q16637-2]
DR   RefSeq; NP_075015.1; NM_022877.2. [Q16637-4]
DR   RefSeq; XP_016865275.1; XM_017009786.1. [Q16637-4]
DR   PDB; 1G5V; NMR; -; A=82-169.
DR   PDB; 1MHN; X-ray; 1.80 A; A=89-147.
DR   PDB; 2LEH; NMR; -; B=26-51.
DR   PDB; 4A4E; NMR; -; A=84-147.
DR   PDB; 4A4G; NMR; -; A=84-147.
DR   PDB; 4GLI; X-ray; 1.90 A; A=263-294.
DR   PDB; 4QQ6; X-ray; 1.75 A; A=82-147.
DR   PDB; 5XJL; X-ray; 2.50 A; M=26-62.
DR   PDB; 5XJQ; X-ray; 3.28 A; M=26-62.
DR   PDB; 5XJR; X-ray; 3.12 A; M=26-62.
DR   PDB; 5XJS; X-ray; 3.38 A; M=26-62.
DR   PDB; 5XJT; X-ray; 2.92 A; M=26-62.
DR   PDB; 5XJU; X-ray; 2.58 A; M=26-62.
DR   PDBsum; 1G5V; -.
DR   PDBsum; 1MHN; -.
DR   PDBsum; 2LEH; -.
DR   PDBsum; 4A4E; -.
DR   PDBsum; 4A4G; -.
DR   PDBsum; 4GLI; -.
DR   PDBsum; 4QQ6; -.
DR   PDBsum; 5XJL; -.
DR   PDBsum; 5XJQ; -.
DR   PDBsum; 5XJR; -.
DR   PDBsum; 5XJS; -.
DR   PDBsum; 5XJT; -.
DR   PDBsum; 5XJU; -.
DR   BMRB; Q16637; -.
DR   SMR; Q16637; -.
DR   BioGRID; 112490; 260.
DR   BioGRID; 112491; 67.
DR   ComplexPortal; CPX-6031; SMN complex.
DR   CORUM; Q16637; -.
DR   DIP; DIP-31309N; -.
DR   IntAct; Q16637; 239.
DR   MINT; Q16637; -.
DR   STRING; 9606.ENSP00000370119; -.
DR   BindingDB; Q16637; -.
DR   ChEMBL; CHEMBL1293232; -.
DR   iPTMnet; Q16637; -.
DR   PhosphoSitePlus; Q16637; -.
DR   BioMuta; SMN1; -.
DR   DMDM; 2498924; -.
DR   EPD; Q16637; -.
DR   jPOST; Q16637; -.
DR   MassIVE; Q16637; -.
DR   MaxQB; Q16637; -.
DR   PaxDb; Q16637; -.
DR   PeptideAtlas; Q16637; -.
DR   PRIDE; Q16637; -.
DR   ProteomicsDB; 60992; -. [Q16637-1]
DR   ProteomicsDB; 60993; -. [Q16637-2]
DR   ProteomicsDB; 60994; -. [Q16637-3]
DR   ProteomicsDB; 60995; -. [Q16637-4]
DR   Antibodypedia; 12087; 438 antibodies.
DR   Antibodypedia; 3991; 227 antibodies.
DR   DNASU; 6606; -.
DR   DNASU; 6607; -.
DR   Ensembl; ENST00000351205; ENSP00000305857; ENSG00000172062. [Q16637-1]
DR   Ensembl; ENST00000380707; ENSP00000370083; ENSG00000172062. [Q16637-1]
DR   Ensembl; ENST00000380741; ENSP00000370117; ENSG00000205571. [Q16637-1]
DR   Ensembl; ENST00000380742; ENSP00000370118; ENSG00000205571. [Q16637-2]
DR   Ensembl; ENST00000380743; ENSP00000370119; ENSG00000205571. [Q16637-1]
DR   Ensembl; ENST00000503079; ENSP00000428128; ENSG00000172062. [Q16637-2]
DR   Ensembl; ENST00000506163; ENSP00000424926; ENSG00000172062. [Q16637-3]
DR   Ensembl; ENST00000611442; ENSP00000483768; ENSG00000277773. [Q16637-2]
DR   Ensembl; ENST00000614240; ENSP00000479279; ENSG00000205571. [Q16637-2]
DR   Ensembl; ENST00000614610; ENSP00000479920; ENSG00000273772. [Q16637-1]
DR   Ensembl; ENST00000614773; ENSP00000481427; ENSG00000273772. [Q16637-2]
DR   Ensembl; ENST00000618251; ENSP00000483515; ENSG00000277773. [Q16637-1]
DR   Ensembl; ENST00000618661; ENSP00000483819; ENSG00000277773. [Q16637-1]
DR   Ensembl; ENST00000622158; ENSP00000480906; ENSG00000275349. [Q16637-2]
DR   Ensembl; ENST00000622739; ENSP00000482966; ENSG00000275349. [Q16637-1]
DR   Ensembl; ENST00000624634; ENSP00000485595; ENSG00000277773. [Q16637-2]
DR   Ensembl; ENST00000626847; ENSP00000486152; ENSG00000205571. [Q16637-3]
DR   Ensembl; ENST00000627341; ENSP00000487421; ENSG00000273772. [Q16637-1]
DR   Ensembl; ENST00000628353; ENSP00000487029; ENSG00000275349. [Q16637-3]
DR   Ensembl; ENST00000628642; ENSP00000487015; ENSG00000273772. [Q16637-3]
DR   Ensembl; ENST00000629122; ENSP00000487206; ENSG00000275349. [Q16637-1]
DR   GeneID; 6606; -.
DR   GeneID; 6607; -.
DR   KEGG; hsa:6606; -.
DR   KEGG; hsa:6607; -.
DR   UCSC; uc003jyd.4; human. [Q16637-1]
DR   CTD; 6606; -.
DR   CTD; 6607; -.
DR   DisGeNET; 6606; -.
DR   DisGeNET; 6607; -.
DR   GeneCards; SMN1; -.
DR   GeneCards; SMN2; -.
DR   GeneReviews; SMN1; -.
DR   GeneReviews; SMN2; -.
DR   HGNC; HGNC:11117; SMN1.
DR   HGNC; HGNC:11118; SMN2.
DR   HPA; ENSG00000172062; Low tissue specificity.
DR   HPA; ENSG00000205571; Low tissue specificity.
DR   MalaCards; SMN1; -.
DR   MalaCards; SMN2; -.
DR   MIM; 253300; phenotype.
DR   MIM; 253400; phenotype.
DR   MIM; 253550; phenotype.
DR   MIM; 271150; phenotype.
DR   MIM; 600354; gene.
DR   MIM; 601627; gene.
DR   neXtProt; NX_Q16637; -.
DR   OpenTargets; ENSG00000172062; -.
DR   OpenTargets; ENSG00000205571; -.
DR   Orphanet; 83330; Proximal spinal muscular atrophy type 1.
DR   Orphanet; 83418; Proximal spinal muscular atrophy type 2.
DR   Orphanet; 83419; Proximal spinal muscular atrophy type 3.
DR   Orphanet; 83420; Proximal spinal muscular atrophy type 4.
DR   PharmGKB; PA35967; -.
DR   VEuPathDB; HostDB:ENSG00000172062.16; -.
DR   VEuPathDB; HostDB:ENSG00000205571.12; -.
DR   eggNOG; KOG4327; Eukaryota.
DR   GeneTree; ENSGT00940000153352; -.
DR   HOGENOM; CLU_077852_0_0_1; -.
DR   InParanoid; Q16637; -.
DR   OrthoDB; 1316275at2759; -.
DR   PhylomeDB; Q16637; -.
DR   TreeFam; TF318390; -.
DR   PathwayCommons; Q16637; -.
DR   Reactome; R-HSA-191859; snRNP Assembly.
DR   SIGNOR; Q16637; -.
DR   BioGRID-ORCS; 6606; 27 hits in 177 CRISPR screens.
DR   BioGRID-ORCS; 6607; 396 hits in 543 CRISPR screens.
DR   ChiTaRS; SMN1; human.
DR   ChiTaRS; SMN2; human.
DR   EvolutionaryTrace; Q16637; -.
DR   GeneWiki; SMN1; -.
DR   GeneWiki; SMN2; -.
DR   Pharos; Q16637; Tbio.
DR   PRO; PR:Q16637; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q16637; protein.
DR   Bgee; ENSG00000172062; Expressed in ventricular zone and 112 other tissues.
DR   ExpressionAtlas; Q16637; baseline and differential.
DR   Genevisible; Q16637; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0015030; C:Cajal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0097504; C:Gemini of coiled bodies; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IDA:UniProtKB.
DR   GO; GO:0032797; C:SMN complex; IDA:UniProtKB.
DR   GO; GO:0034719; C:SMN-Sm protein complex; IDA:UniProtKB.
DR   GO; GO:0030018; C:Z disc; IEA:UniProtKB-SubCell.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0006353; P:DNA-templated transcription, termination; IMP:UniProtKB.
DR   GO; GO:0051170; P:import into nucleus; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0000245; P:spliceosomal complex assembly; IMP:UniProtKB.
DR   GO; GO:0000387; P:spliceosomal snRNP assembly; IDA:UniProtKB.
DR   CDD; cd04508; TUDOR; 1.
DR   IDEAL; IID00569; -.
DR   InterPro; IPR010304; Survival_motor_neuron.
DR   InterPro; IPR002999; Tudor.
DR   Pfam; PF06003; SMN; 1.
DR   SMART; SM00333; TUDOR; 1.
DR   PROSITE; PS50304; TUDOR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell projection;
KW   Cytoplasm; Disease variant; Isopeptide bond; mRNA processing;
KW   mRNA splicing; Neurodegeneration; Neurogenesis; Nucleus; Phosphoprotein;
KW   Reference proteome; RNA-binding; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..294
FT                   /note="Survival motor neuron protein"
FT                   /id="PRO_0000218903"
FT   DOMAIN          91..151
FT                   /note="Tudor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00211"
FT   REGION          13..44
FT                   /note="P1 (binding site for GEMIN2)"
FT   REGION          97..209
FT                   /note="Required for interaction with RPP20/POP7"
FT   REGION          240..267
FT                   /note="P2 (binding site for SNRPB)"
FT   REGION          279..294
FT                   /note="Required for interaction with SYNCRIP"
FT                   /evidence="ECO:0000269|PubMed:11574476"
FT   COMPBIAS        195..203
FT                   /note="Poly-Pro"
FT   COMPBIAS        217..226
FT                   /note="Poly-Pro"
FT   COMPBIAS        244..248
FT                   /note="Poly-Pro"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         4
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21609790,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         5
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21609790,
FT                   ECO:0007744|PubMed:21406692"
FT   MOD_RES         8
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21609790,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         25
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         28
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:17487921, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         69
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         85
FT                   /note="Phosphothreonine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21609790"
FT   MOD_RES         187
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:21609790"
FT   CROSSLNK        51
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        209
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         210..241
FT                   /note="Missing (in isoform SMN-delta5 and isoform SMN-
FT                   delta57)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_006183"
FT   VAR_SEQ         279..282
FT                   /note="GFRQ -> EMLA (in isoform SMN-delta7 and isoform SMN-
FT                   delta57)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006184"
FT   VAR_SEQ         283..294
FT                   /note="Missing (in isoform SMN-delta7 and isoform SMN-
FT                   delta57)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006185"
FT   VARIANT         2
FT                   /note="A -> G (in SMA2 and SMA3; dbSNP:rs75030631)"
FT                   /evidence="ECO:0000269|PubMed:9837824"
FT                   /id="VAR_005615"
FT   VARIANT         30
FT                   /note="D -> N (in SMA2; dbSNP:rs104893930)"
FT                   /evidence="ECO:0000269|PubMed:15580564"
FT                   /id="VAR_034803"
FT   VARIANT         44
FT                   /note="D -> V (in SMA3; dbSNP:rs104893931)"
FT                   /evidence="ECO:0000269|PubMed:15580564"
FT                   /id="VAR_034804"
FT   VARIANT         95
FT                   /note="G -> R (in SMA3; reduces SMN binding to Sm proteins;
FT                   dbSNP:rs104893927)"
FT                   /evidence="ECO:0000269|PubMed:15580564"
FT                   /id="VAR_034805"
FT   VARIANT         111
FT                   /note="A -> G (in SMA2; reduces SMN binding to Sm proteins;
FT                   abolishes the interaction with ELAVL4; dbSNP:rs104893935)"
FT                   /evidence="ECO:0000269|PubMed:15580564,
FT                   ECO:0000269|PubMed:21088113"
FT                   /id="VAR_034806"
FT   VARIANT         116
FT                   /note="I -> F (in SMA1; abolishes the interaction with
FT                   ELAVL4; dbSNP:rs104893933)"
FT                   /evidence="ECO:0000269|PubMed:15249625,
FT                   ECO:0000269|PubMed:21088113"
FT                   /id="VAR_034807"
FT   VARIANT         136
FT                   /note="Q -> E (in SMA1; abolishes the interaction with
FT                   ELAVL4; dbSNP:rs104893934)"
FT                   /evidence="ECO:0000269|PubMed:15249625,
FT                   ECO:0000269|PubMed:21088113"
FT                   /id="VAR_034808"
FT   VARIANT         245
FT                   /note="P -> L (in SMA3; dbSNP:rs75586164)"
FT                   /evidence="ECO:0000269|PubMed:10732817"
FT                   /id="VAR_010051"
FT   VARIANT         262
FT                   /note="S -> G (in SMA3; dbSNP:rs104893932)"
FT                   /evidence="ECO:0000269|PubMed:15580564"
FT                   /id="VAR_034809"
FT   VARIANT         262
FT                   /note="S -> I (in SMA3; slightly reduces SMN binding to
FT                   RPP20/POP7; dbSNP:rs75660264)"
FT                   /evidence="ECO:0000269|PubMed:14715275,
FT                   ECO:0000269|PubMed:9158159"
FT                   /id="VAR_005616"
FT   VARIANT         272
FT                   /note="Y -> C (in SMA1; abolishes SMN binding to RPP20/
FT                   POP7; dbSNP:rs104893922)"
FT                   /evidence="ECO:0000269|PubMed:10732817,
FT                   ECO:0000269|PubMed:14715275, ECO:0000269|PubMed:15580564,
FT                   ECO:0000269|PubMed:7813012"
FT                   /id="VAR_005617"
FT   VARIANT         274
FT                   /note="T -> I (in SMA2 and SMA3; reduces SMN binding to
FT                   RPP20/POP7; dbSNP:rs76871093)"
FT                   /evidence="ECO:0000269|PubMed:14715275,
FT                   ECO:0000269|PubMed:15580564, ECO:0000269|PubMed:9158159"
FT                   /id="VAR_005618"
FT   VARIANT         275
FT                   /note="G -> S (in SMA3; dbSNP:rs77301881)"
FT                   /evidence="ECO:0000269|PubMed:9837824"
FT                   /id="VAR_005619"
FT   VARIANT         279
FT                   /note="G -> C (in SMA2 and SMA3; dbSNP:rs77969175)"
FT                   /evidence="ECO:0000269|PubMed:10732802"
FT                   /id="VAR_007990"
FT   VARIANT         279
FT                   /note="G -> V (in SMA1; slightly reduces SMN binding to
FT                   RPP20/POP7. Impairs dimerization and axon localization;
FT                   dbSNP:rs76163360)"
FT                   /evidence="ECO:0000269|PubMed:14715275,
FT                   ECO:0000269|PubMed:21389246, ECO:0000269|PubMed:9147655"
FT                   /id="VAR_005620"
FT   MUTAGEN         134
FT                   /note="E->K: Reduces SMN binding to RPP20/POP7. Abolishes
FT                   the interaction with ELAVL4."
FT                   /evidence="ECO:0000269|PubMed:14715275,
FT                   ECO:0000269|PubMed:21088113, ECO:0000269|PubMed:21389246,
FT                   ECO:0000269|PubMed:29061699"
FT   HELIX           38..48
FT                   /evidence="ECO:0007744|PDB:5XJL"
FT   TURN            87..90
FT                   /evidence="ECO:0007744|PDB:4A4E"
FT   STRAND          97..101
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   TURN            103..105
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   STRAND          108..117
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   TURN            118..121
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   STRAND          122..127
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   TURN            128..130
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   STRAND          133..137
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   HELIX           138..140
FT                   /evidence="ECO:0007744|PDB:4QQ6"
FT   HELIX           263..280
FT                   /evidence="ECO:0007744|PDB:4GLI"
SQ   SEQUENCE   294 AA;  31849 MW;  8A9A2A94192DCB9B CRC64;
     MAMSSGGSGG GVPEQEDSVL FRRGTGQSDD SDIWDDTALI KAYDKAVASF KHALKNGDIC
     ETSGKPKTTP KRKPAKKNKS QKKNTAASLQ QWKVGDKCSA IWSEDGCIYP ATIASIDFKR
     ETCVVVYTGY GNREEQNLSD LLSPICEVAN NIEQNAQENE NESQVSTDES ENSRSPGNKS
     DNIKPKSAPW NSFLPPPPPM PGPRLGPGKP GLKFNGPPPP PPPPPPHLLS CWLPPFPSGP
     PIIPPPPPIC PDSLDDADAL GSMLISWYMS GYHTGYYMGF RQNQKEGRCS HSLN
//
